Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B
Top Page
Clinical Laserthermia Systems AB Class B
(CLS.B)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr4.50
▼(-33.73% Downside)
Action:ReiteratedDate:02/27/26
The score is held down primarily by weak financial performance (large ongoing losses, negative margins, and continued cash burn) and bearish technicals (price below key moving averages and negative MACD). A low-debt balance sheet provides some support, while valuation is not clearly attractive given negative earnings and no dividend data.
Positive Factors
Low leverage / clean balance sheet
Net-zero debt and meaningful equity provide structural financial flexibility. A low-leverage profile reduces bankruptcy risk, supports access to financing on better terms, and gives management time to execute clinical commercialization without immediate debt pressures.
Negative Factors
Deep, persistent losses
Very large negative margins indicate the core offering is not yet commercially profitable. Persistent heavy losses erode equity, limit reinvestment in commercialization, and require continued external funding, which can dilute shareholders and stress long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / clean balance sheet
Net-zero debt and meaningful equity provide structural financial flexibility. A low-leverage profile reduces bankruptcy risk, supports access to financing on better terms, and gives management time to execute clinical commercialization without immediate debt pressures.
Read all positive factors
Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr143.37M
Dividend YieldN/A
Average Volume (3M)333.29K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth14.18%
EPS Growth72.73%
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.39
Shares Outstanding31,163,593
10 Day Avg. Volume370,302
30 Day Avg. Volume333,294
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr54.20M
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company Description
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also prov...
How the Company Makes Money
CLS generates revenue primarily by selling (or otherwise providing under commercial agreements) its laserthermia ablation platform and related procedure components to healthcare providers and partners. Key revenue streams are expected to include: ...
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.49M | 18.78M | 8.27M | 6.27M | 2.25M |
| Gross Profit | -29.00M | 10.42M | 3.00M | -2.79M | -3.63M |
| EBITDA | -26.41M | -44.76M | -68.41M | -57.84M | -57.05M |
| Net Income | -41.61M | -47.62M | -79.79M | -70.66M | -63.62M |
Balance Sheet | |||||
| Total Assets | 76.49M | 78.56M | 57.73M | 49.51M | 66.74M |
| Cash, Cash Equivalents and Short-Term Investments | 21.55M | 22.51M | 15.33M | 10.59M | 31.17M |
| Total Debt | 0.00 | 224.00K | 454.00K | 30.68M | 273.50K |
| Total Liabilities | 10.00M | 12.88M | 14.20M | 41.64M | 45.55M |
| Stockholders Equity | 69.67M | 68.72M | 45.77M | 9.22M | 21.79M |
Cash Flow | |||||
| Free Cash Flow | -35.91M | -58.92M | -71.95M | -71.25M | -66.73M |
| Operating Cash Flow | -33.20M | -56.45M | -66.45M | -70.69M | -66.17M |
| Investing Cash Flow | -2.80M | -7.47M | -5.50M | -886.00K | -408.00K |
| Financing Cash Flow | 35.04M | 71.10M | 76.69M | 61.84M | 85.88M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Negative
6.79
Price Trends
6.55
Negative
7.06
Negative
6.75
Negative
Market Momentum
-0.52
Positive
32.06
Neutral
30.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 6.79 is above the 20-day moving average (MA) of 5.23, above the 50-day MA of 6.55, and above the 200-day MA of 6.75, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 32.06 is Neutral, neither overbought nor oversold. The STOCH value of 30.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr117.62M | 20.88 | ― | ― | ― | ― | |
54 Neutral | kr136.07M | -17.89 | ― | ― | 17.24% | 35.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr143.37M | -4.28 | -61.62% | ― | 14.18% | 72.73% | |
44 Neutral | kr46.85M | -2.89 | -60.56% | ― | 163.12% | 30.50% | |
43 Neutral | kr51.24M | -1.14 | -50.21% | ― | ― | -108.64% | |
43 Neutral | kr134.97M | -1.96 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.60
1.76
61.97%
SE:SPEC
SpectraCure AB
0.09
-0.70
-88.68%
SE:LXB
Luxbright AB
0.36
-0.49
-57.65%
SE:HEART
Scandinavian Real Heart AB
13.50
-1.35
-9.07%
SE:NOSA
Nosa Plugs AB
0.52
-0.26
-32.95%
SE:ARCOMA
Arcoma AB
8.22
-1.64
-16.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.